Amgen Looks To Build On Blincyto Momentum As It Enters A Year Loaded With Milestones
Executive Summary
Three 2015 filings play a key role in the big biotech offsetting expected revenue declines for four legacy products. The biggest test will be the showdown between its PCSK9 inhibitor evolocumab and Sanofi/Regeneron’s competing alirocumab, which is expected to reach market first.